Literature DB >> 15389586

Spreading of embryologically distinct urothelial cells is inhibited by SPARC.

Amber E Hudson1, Waldo C Feng, Catherine F Delostrinos, Nicole Carmean, James A Bassuk.   

Abstract

The AON epitope of secreted protein acidic and rich in cysteine (SPARC) is a conserved motif expressed by human SPARC in a variety of human cell types. Through the use of a monoclonal antibody that recognizes this epitope, transitional epithelium was found to restrict expression of SPARC to the suprabasal and intermediate layer. Such intracellular expression was defined by immunoreactive signals that localized to the apical plasma membranes of suprabasal and intermediate cells. Polarization of SPARC to apical plasma membranes of suprabasal cells was retained in vitro by a subpopulation of cells that exhibited characteristics of suprabasal cells--cell-cycle quiescence, large cell volumes, and multiple nuclei. In contrast, the basal layer of transitional epithelium in vivo and cycling cells in vitro did not exhibit this apical staining pattern, but instead sequestered the SPARC polypeptide within urothelial cytoplasm and/or nuclei, as revealed by immunohistochemical analysis. Elution of soluble proteins and DNA from urothelial cells revealed the presence of SPARC within the nuclear matrix--and that SPARC colocalized with the nuclear matrix Ki-67 antigen. rSPARC activity was demonstrated and quantified with a rounding assay whereby the spreading of freshly plated cells was inhibited by recombinant SPARC in a concentration- and time-dependent manner. Inhibition of spreading was observed in urothelial cells derived from endoderm (bladder) and mesoderm (ureter) germ layers. Statistically significant differences were seen between urothelial cells from these two layers. Mesodermal cells recovered more slowly from the inhibitory effects of rSPARC, such that at hour 6 endodermal cells underwent significantly more spreading, as shown by a rounding index (RI). These experiments provide new insights about the matricellular trafficking of SPARC and suggest that intra- and extra-cellular localization patterns influence the development, homeostasis, and differentiation of transitional epithelium. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389586     DOI: 10.1002/jcp.20140

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Immortalization of human urothelial cells by human papillomavirus type 16 E6 and E7 genes in a defined serum-free system.

Authors:  N Carmean; J W Kosman; E M Leaf; A E Hudson; K E Opheim; J A Bassuk
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

2.  Dual sources of vitronectin in the human lower urinary tract: synthesis by urothelium vs. extravasation from the bloodstream.

Authors:  Dianzhong Zhang; Amber E Hudson; Catherine F Delostrinos; Nicole Carmean; Rocky Eastman; Bryson Hicks; Robert E Hurst; James A Bassuk
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-03

3.  miR-8 modulates cytoskeletal regulators to influence cell survival and epithelial organization in Drosophila wings.

Authors:  Kelsey Bolin; Nicholas Rachmaninoff; Kea Moncada; Katharine Pula; Jennifer Kennell; Laura Buttitta
Journal:  Dev Biol       Date:  2016-02-21       Impact factor: 3.582

4.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Authors:  Joaquim Bellmunt; Hans von der Maase; Graham M Mead; Iwona Skoneczna; Maria De Santis; Gedske Daugaard; Andreas Boehle; Christine Chevreau; Luis Paz-Ares; Leslie R Laufman; Eric Winquist; Derek Raghavan; Sandrine Marreaud; Sandra Collette; Richard Sylvester; Ronald de Wit
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

5.  SPARC gene expression is repressed in human urothelial cells (UROtsa) exposed to or malignantly transformed by cadmium or arsenite.

Authors:  Jennifer Larson; Tahmina Yasmin; Donald A Sens; Xu Dong Zhou; Mary Ann Sens; Scott H Garrett; Jane R Dunlevy; Ling Cao; Seema Somji
Journal:  Toxicol Lett       Date:  2010-09-16       Impact factor: 4.372

6.  Loss of SPARC in bladder cancer enhances carcinogenesis and progression.

Authors:  Neveen Said; Henry F Frierson; Marta Sanchez-Carbayo; Rolf A Brekken; Dan Theodorescu
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

7.  SPARC Expression Is Selectively Suppressed in Tumor Initiating Urospheres Isolated from As+3- and Cd+2-Transformed Human Urothelial Cells (UROtsa) Stably Transfected with SPARC.

Authors:  Andrea Slusser-Nore; Jennifer L Larson-Casey; Ruowen Zhang; Xu Dong Zhou; Seema Somji; Scott H Garrett; Donald A Sens; Jane R Dunlevy
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

Review 8.  Upper tract urothelial carcinoma: a different disease entity in terms of management.

Authors:  Jeffrey J Leow; Kian Tai Chong; Steven L Chang; Joaquim Bellmunt
Journal:  ESMO Open       Date:  2017-01-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.